Orally Delivered Thioketal Nanoparticles Loaded with TNF-α-siRNA Target Inflammation and Inhibit Gene Expression in the Intestines

Overview

Journal Nat Mater

Date 2010 Oct 12

PMID 20935658

Citations 186

Authors

D Scott Wilson

Guillaume Dalmasso

Lixin Wang

Shanthi V Sitaraman

Didier Merlin

Niren Murthy

Affiliations

Soon will be listed here.

Abstract

Small interfering RNAs (siRNAs) directed against proinflammatory cytokines have the potential to treat numerous diseases associated with intestinal inflammation; however, the side-effects caused by the systemic depletion of cytokines demands that the delivery of cytokine-targeted siRNAs be localized to diseased intestinal tissues. Although various delivery vehicles have been developed to orally deliver therapeutics to intestinal tissue, none of these strategies has demonstrated the ability to protect siRNA from the harsh environment of the gastrointestinal tract and target its delivery to inflamed intestinal tissue. Here, we present a delivery vehicle for siRNA, termed thioketal nanoparticles (TKNs), that can localize orally delivered siRNA to sites of intestinal inflammation, and thus inhibit gene expression in inflamed intestinal tissue. TKNs are formulated from a polymer, poly-(1,4-phenyleneacetone dimethylene thioketal), that degrades selectively in response to reactive oxygen species (ROS). Therefore, when delivered orally, TKNs release siRNA in response to the abnormally high levels of ROS specific to sites of intestinal inflammation. Using a murine model of ulcerative colitis, we demonstrate that orally administered TKNs loaded with siRNA against the proinflammatory cytokine tumour necrosis factor-alpha (TNF-α) diminish TNF-α messenger RNA levels in the colon and protect mice from ulcerative colitis.

Citing Articles

Oral dosage forms for drug delivery to the colon: an existing gap between research and commercial applications.

Martinez E, Gamboa J, Finkielstein C, Canas A, Osorio M, Velez Y J Mater Sci Mater Med. 2025; 36(1):24.

PMID: 40042550 PMC: 11882727. DOI: 10.1007/s10856-025-06868-5.

Exploring precision treatments in immune-mediated inflammatory diseases: Harnessing the infinite potential of nucleic acid delivery.

Xu L, Shao Z, Fang X, Xin Z, Zhao S, Zhang H Exploration (Beijing). 2025; 5(1):20230165.

PMID: 40040830 PMC: 11875455. DOI: 10.1002/EXP.20230165.

A self-sacrificing anti-inflammatory coating promotes simultaneous cardiovascular repair and reendothelialization of implanted devices.

Peng P, Ding S, Liang M, Zheng W, Kang Y, Liu W Bioact Mater. 2025; 47:502-512.

PMID: 40026826 PMC: 11872464. DOI: 10.1016/j.bioactmat.2025.01.037.

Nanosystems for modulation of immune responses in periodontal therapy: a mini-review.

Acharya A, Hegde U, Acharya S Front Dent Med. 2025; 5:1509775.

PMID: 39917718 PMC: 11797770. DOI: 10.3389/fdmed.2024.1509775.

Integrin-Specific Stimuli-Responsive Nanomaterials for Cancer Theranostics.

Taheri Z, Mozafari N, Moradian G, Lovison D, Dehshahri A, De Marco R Pharmaceutics. 2024; 16(11).

PMID: 39598564 PMC: 11597626. DOI: 10.3390/pharmaceutics16111441.

References

Zhang S, Zhao B, Jiang H, Wang B, Ma B . Cationic lipids and polymers mediated vectors for delivery of siRNA. J Control Release. 2007; 123(1):1-10. DOI: 10.1016/j.jconrel.2007.07.016. View

Lamprecht A, Schafer U, Lehr C . Size-dependent bioadhesion of micro- and nanoparticulate carriers to the inflamed colonic mucosa. Pharm Res. 2001; 18(6):788-93. DOI: 10.1023/a:1011032328064. View

Palliser D, Chowdhury D, Wang Q, Lee S, Bronson R, Knipe D . An siRNA-based microbicide protects mice from lethal herpes simplex virus 2 infection. Nature. 2005; 439(7072):89-94. DOI: 10.1038/nature04263. View

Kountouras J, Chatzopoulos D, Zavos C . Reactive oxygen metabolites and upper gastrointestinal diseases. Hepatogastroenterology. 2001; 48(39):743-51. View

Peer D, Park E, Morishita Y, Carman C, Shimaoka M . Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target. Science. 2008; 319(5863):627-30. PMC: 2490797. DOI: 10.1126/science.1149859. View

Mahida Y, Wu K, Jewell D . Respiratory burst activity of intestinal macrophages in normal and inflammatory bowel disease. Gut. 1989; 30(10):1362-70. PMC: 1434403. DOI: 10.1136/gut.30.10.1362. View

Murata N, Takashima Y, Toyoshima K, Yamamoto M, Okada H . Anti-tumor effects of anti-VEGF siRNA encapsulated with PLGA microspheres in mice. J Control Release. 2008; 126(3):246-54. DOI: 10.1016/j.jconrel.2007.11.017. View

Sedghi S, Fields J, KLAMUT M, Urban G, Durkin M, Winship D . Increased production of luminol enhanced chemiluminescence by the inflamed colonic mucosa in patients with ulcerative colitis. Gut. 1993; 34(9):1191-7. PMC: 1375452. DOI: 10.1136/gut.34.9.1191. View

Yamanaka Y, Leong K . Engineering strategies to enhance nanoparticle-mediated oral delivery. J Biomater Sci Polym Ed. 2008; 19(12):1549-70. DOI: 10.1163/156856208786440479. View

10.

Hariharan S, Bhardwaj V, Bala I, Sitterberg J, Bakowsky U, Kumar M . Design of estradiol loaded PLGA nanoparticulate formulations: a potential oral delivery system for hormone therapy. Pharm Res. 2005; 23(1):184-95. DOI: 10.1007/s11095-005-8418-y. View

11.

Heraganahally S, Au V, Kondru S, Edwards S, Bowden J, Sajkov D . Pulmonary toxicity associated with infliximab therapy for ulcerative colitis. Intern Med J. 2009; 39(9):629-30. DOI: 10.1111/j.1445-5994.2009.001999.x. View

12.

Powell S, Collier K, Reddy G, Cerchia R, Kahn E, Weissman G . Increased oxidative stress and decreased antioxidant defenses in mucosa of inflammatory bowel disease. Dig Dis Sci. 1996; 41(10):2078-86. DOI: 10.1007/BF02093613. View

13.

Leirdal M, Sioud M . Gene silencing in mammalian cells by preformed small RNA duplexes. Biochem Biophys Res Commun. 2002; 295(3):744-8. DOI: 10.1016/s0006-291x(02)00736-2. View

14.

Kontoyiannis D, Pasparakis M, Pizarro T, Cominelli F, Kollias G . Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for joint and gut-associated immunopathologies. Immunity. 1999; 10(3):387-98. DOI: 10.1016/s1074-7613(00)80038-2. View

15.

Desai M, Labhasetwar V, Amidon G, Levy R . Gastrointestinal uptake of biodegradable microparticles: effect of particle size. Pharm Res. 1996; 13(12):1838-45. DOI: 10.1023/a:1016085108889. View

16.

Aouadi M, Tesz G, Nicoloro S, Wang M, Chouinard M, Soto E . Orally delivered siRNA targeting macrophage Map4k4 suppresses systemic inflammation. Nature. 2009; 458(7242):1180-4. PMC: 2879154. DOI: 10.1038/nature07774. View

17.

Wirtz S, Neufert C, Weigmann B, Neurath M . Chemically induced mouse models of intestinal inflammation. Nat Protoc. 2007; 2(3):541-6. DOI: 10.1038/nprot.2007.41. View

18.

Thiele L, Rothen-Rutishauser B, Jilek S, Wunderli-Allenspach H, Merkle H, Walter E . Evaluation of particle uptake in human blood monocyte-derived cells in vitro. Does phagocytosis activity of dendritic cells measure up with macrophages?. J Control Release. 2001; 76(1-2):59-71. DOI: 10.1016/s0168-3659(01)00412-6. View

19.

Reddy J, Loftus Jr E . Safety of infliximab and other biologic agents in the inflammatory bowel diseases. Gastroenterol Clin North Am. 2006; 35(4):837-55. DOI: 10.1016/j.gtc.2006.09.008. View

20.

Pertuit D, Moulari B, Betz T, Nadaradjane A, Neumann D, Ismaili L . 5-amino salicylic acid bound nanoparticles for the therapy of inflammatory bowel disease. J Control Release. 2007; 123(3):211-8. DOI: 10.1016/j.jconrel.2007.08.008. View